Most importantly, in line with a 2022 expert consensus about kidney function monitoring in IBD,17 our findings on the association of TNF inhibitor use with progressive eGFR decline suggest the need for careful assessment and monitoring of kidney function when initiating anti-TNF therapy in patients with IBD. The gene discussed is TNF; the disease is inflammatory bowel disease.